Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM study of AZD5148 to prevent recurrent Clostridioides difficile infection
jRCT2031250579Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of azd5148 in Clostridioides difficile colitis (CDI), sponsored by AstraZeneca. Started Feb 2026; status: recruiting.
02
Drugs
azd5148
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on jRCT2031250579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250579.